Current role
Biotechnology · Healthcare
CEO, Board Member
2025-08-11–present
Eli Wallace
Equibles does not estimate personal net worth.
About Eli Wallace
Eli Wallace is recorded as Board Member at BridgeBio Oncology Therapeutics, Inc. (BBOT) since August 11, 2025 and CEO at BridgeBio Oncology Therapeutics, Inc. (BBOT). BridgeBio Oncology Therapeutics, Inc. reported in an 8-K filed April 29, 2026 that Eli Wallace resigned as member of the Company's Board of Directors and as a Class III director, effective April 20, 2026. BridgeBio Oncology Therapeutics, Inc. reported in an 8-K filed April 23, 2026 that Eli Wallace resigned as Class III director, effective April 20, 2026. BridgeBio Oncology Therapeutics, Inc. reported in an 8-K filed August 13, 2025 that Eli Wallace was appointed Chief Executive Officer, effective May 1, 2024. Equibles holds 5 filed executive changes naming Eli Wallace; each is listed under recent activity with its source filing. The proxy statement of BridgeBio Oncology Therapeutics, Inc. reports total compensation of $11,489,545 for Eli Wallace in fiscal 2025, including a base salary of $571,850. Disclosed compensation is on record for 2 fiscal years. BridgeBio Oncology Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at BridgeBio Oncology Therapeutics, Inc. includes Pedro Beltran, Ph.D. (CEO and Board Member), Pedro J. Beltran, Ph.D. (CEO and Board Member), Neil Kumar, Ph.D. (Chairman) and 7 others.
“Eli Wallace, Ph.D. resigned from his position as a member of the Company's Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company's President and Chief Executive Officer, effective on April 20, 2026.”
“Dr. Wallace resigned from his position as a member of the Board and as a Class III director, and the Board appointed Dr. Beltran as a Class III director to fill the vacancy created by Dr. Wallace’s resignation, effective immediately.”
Affiliation history
-
Current
2025-08-11–present
-
Current
-
2025-08-11–2026-04-20
Company network
Leadership on record at BridgeBio Oncology Therapeutics, Inc.
- Pedro Beltran, Ph.D. CEO, Board Member
- Pedro J. Beltran, Ph.D. CEO, Board Member
- Neil Kumar, Ph.D. Chairman
- Idan Elmelech CFO, COO
- Uneek Mehra CFO
- Marc Cobo Chief Accounting Officer
- Albert A. Holman, III Board Member
- Bihua Chen Board Member
- Frank McCormick Board Member
- Frank P. McCormick Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | BridgeBio Oncology Therapeutics, Inc. (BBOT) | Former President and Chief Executive Officer | $571,850 | $11,489,545 |
| 2024 | BridgeBio Oncology Therapeutics, Inc. (BBOT) | Former President and Chief Executive Officer | $544,154 | $4,463,320 |